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Abstract: This study was conducted to investigate the effect of topical tacrolimus (0.1%) ointment in stimulating tear production in
dogs with keratoconjunctivitis sicca (KCS). Thirty-six dogs (58 eyes) diagnosed with KCS were included in this study. KCS was grouped
as early (E, n = 21 eyes), late (L, n = 21 eyes), and reflex tear due to corneal ulceration (R, n = 16 eyes) based on Schirmer tear test
(STT) readings. The dogs in each group were randomly allotted treatment with either tacrolimus 0.1% ointment applied once daily
(ET, n = 11 eyes; LT, n = 10 eyes; RT, n = 6 eyes) or cyclosporine (CsA) 0.05% eye drops instilled five times daily (EC, n = 10 eyes;
LC, n = 11 eyes; RC, n = 10 eyes) for 2 months. The efficacy of the treatments was evaluated and comparison was made based on
complete ophthalmic examination and a scoring system for various parameters like menace reflex, palpebral reflex, pupillary light
reflex, conjunctival hyperemia, ocular discharge, corneal clarity, corneal ulceration, corneal vessel length, corneal vessel density, corneal
pigmentation area, corneal pigmentation density, STT readings, fluorescein dye test, and Rose Bengal dye test. The effect of treatment
was evaluated on day 15, 30, and 60 after treatments. Good quality digital photographs from a fixed distance were taken at each interval
to aid subjective evaluation. Data were analyzed using one-way and repeated-measures ANOVA followed by Tukey’s HSD test, Wilcoxon
signed rank test, and Kruskal–Wallis test followed by Dunn’s test to identify significant interactions. The level of significance was set
to P < 0.05. Improvement in menace reflex and pupillary light reflex was observed in both treatment groups. Conjunctival hyperemia
and ocular discharge decreased significantly after treatment with both of the drugs. There was no significant difference in improvement
in tear production between treatment groups but tacrolimus 0.1% ointment significantly arrested the progression of pigments. The
study concluded that both tacrolimus 0.1% ointment and CsA 0.05% eye drops improve tear production in KCS-affected dogs. Topical
tacrolimus 0.1% ointment effectively arrests the progression of pigmentation compared to CsA 0.05% eye drops in KCS-affected dogs.
Key words: Tacrolimus, cyclosporine, lacrimostimulant, keratoconjunctivitis sicca, dogs

1. Introduction
Keratoconjunctivitis sicca (KCS), or dry eye, is a local
immune-mediated disease that leads to the deficiency of
precorneal tear film, which is crucial for preserving ocular
surface health (1,2). The unrefreshed tear film, having
altered composition like elevated tear osmolarity and the
presence of proinflammatory mediators and proteases,
no longer supports the normal functioning of the ocular
surface (3). The deficiency in the aqueous component of
the tear film predisposes the ocular surface to infection
(4) and subsequent complications such as ulceration,
vascularization, fibrosis, and pigmentation (1). Though
there are several causes of KCS such as drug-induced
toxicity, neurogenic or endocrine factors, hypoplasia, or
adenitis of the lacrimal glands, a local immune-mediated
destruction of the lacrimal glands was established in

histological studies (5).The risk factors for KCS are aging,
breed predisposition in brachycephalic dogs, hormonal
changes, and systemic diseases (1,3,6–8).
Stimulation of natural tear production was the mainstay
of treatment for KCS to reduce associated clinical signs
and thereby prevent loss of vision (9). The calcineurin
inhibitors, cyclosporine A (CsA) and tacrolimus, are the
lacrimostimulants widely used in dogs with KCS. CsA is
the most commonly used lacrimostimulant for dogs with
KCS either in the form of ointment (0.2%) or as an oil-based
suspension (1%–2%). It has unique noncytotoxic effects on
T cells at therapeutic concentrations and acts by inhibiting
T-cell proliferation, allows regeneration of lacrimal glands
and acini, and supports the secretory function (10). CsA
has antiinflammatory properties on ocular tissues, prevents
lacrimal gland apoptosis, and has a proliferative effect on
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conjunctival goblet cells stimulating mucin production. It
also has potent immunosuppressive properties, reflecting
its ability to block the transcription of cytokine genes in
activated T cells (9–14). Tacrolimus (formerly FK506) is
a macrolide antibiotic from Streptomyces tsukubaensis
that shows similarities to the immunomodulatory action
of CsA (10,15). CsA therapy has been found to be less
effective in bringing back tear production to normal levels
and is an irritant to ocular tissues. It also fails to prevent
the progression of corneal pigmentation in eyes severely
affected with KCS (9). Topical administration of a 0.02%
aqueous suspension of tacrolimus was found to enhance
tear production in dogs with KCS (9). There are only a few
studies on the effects of commercially available tacrolimus
0.1% ointment topically in eyes of dogs affected with KCS.
This study was hence conducted with the aim of evaluating
the efficacy of topical tacrolimus 0.1% ointment applied
once a day and CsA 0.05% eye drops instilled five times a
day in dogs with early and late stages of KCS, and also for
KCS-associated corneal ulceration presented with reflex
tearing.
2. Materials and methods
2.1. Grouping of cases and ophthalmic evaluation
findings
Due permission to conduct the present clinical experiment
was obtained from the Committee for the Purpose of
Control and Supervision of Experiments on Animals,
Ministry of the Environment, Forest, and Climate Change,
Government of India (No. F.25/33/2016-CPCSEA, dated
16/02/2017). This study was conducted in 58 eyes of 36
client-owned dogs with KCS referred to the ophthalmology
units of the clinics. Among a total of 67 dogs diagnosed
with KCS, 31 dogs had KCS due to nonimmune-mediated
causes (iatrogenic, endocrine, drug-induced, or dry eye in
young dogs with viral keratitis) and were excluded from
the study. A detailed history was recorded from the owners
and complete ophthalmic examination was carried out for
all the dogs. The ophthalmological examination included
the Schirmer tear test (STT), indirect ophthalmoscopy,
fluorescein dye test (FDT), Rose Bengal dye (RBD) test,
and complete evaluation of the cornea, anterior and
posterior chamber of the eye, and adnexa. Physiological
parameters like heart rate (HR), respiratory rate (RR),
and rectal temperature (RT) were recorded. Blood
samples were collected and parameters like hemoglobin
(Hb), packed cell volume (PCV), total erythrocyte count
(TEC), total leukocyte count (TLC), and differential
leukocyte count (DLC) were evaluated using standard
procedures. Blood glucose estimations were performed
using a ROMOCHECK glucometer (Romsons Scientific
& Surgical Pvt. Ltd., Nunhai, Agra, Uttar Pradesh, India).
Serum samples were subjected to T4, T3, TSH, and
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cortisol estimation using commercially available ELISA
kits (BlueGene Biotech, Putuo, Shanghai, China). Blood
smears were also evaluated for detecting the presence of
any hemoprotozoan parasites.
The STT was done using Schirmer tear strips (OpStrip,
Ophtechnics Unlimited, Gurgaon, Haryana, India) before
the application of any topical anesthetics. The strips were
placed on the lower fornix of each eye after folding the strip
of filter paper (35 mm × 5 mm) at the notch and putting
the folded portion between the cornea and lower lid. The
paper was left in position for 1 min and the amount of
tear production (mm/min) was measured (16,17). The
STT readings were scored from 1 to 4 in the increasing
order of severity as 1: normal, ≥15 mm/min; 2: mild or
subclinical KCS, 11–14 mm/min; 3: moderate to mild
KCS, 6–10 mm/min; and 4: severe KCS, ≤5 mm/min (18).
The dye-impregnated strips were used for performing
FDT (OptiGlo, Ophtechnics Unlimited) and the RBD
test (Optitech Eye Care, Tarun Enterprises, Allahabad,
Uttar Pradesh, India). These strips were moistened with
sterile normal saline and a drop was placed on the fornix.
The eyes were thoroughly washed with normal saline
and were examined for epithelial loss. The degree of loss
of epithelium was scored from 0 to 2 depending on the
severity as 0: no dye retention, 1: <50% retention of dye,
and 2: >50% retention of dye. The RBD retention intensity
was scored from 0 to 3 in two exposed conjunctival zones
(medial and lateral) and the cornea as 0: no spots, 1: few
separated patches, 2: many separated patches, and 3:
confluent patches. The sum of the scores from each zone
was calculated (maximum of 9) and any value greater than
3 was considered positive for KCS (19).
Depending on the severity of KCS, dogs were grouped
into early (E), late (L), and reflex tear (R) groups. The
dogs with mild and moderate STT readings were placed
in group E (n = 21 eyes). Those dogs with severe STT
scores and mucoid discharge were placed in group L (n
= 21 eyes). The dogs presented with corneal ulceration
of nontraumatic origin along with signs of KCS in the
ipsilateral eye were placed in group R (n = 16 eyes).
Thereafter, the 58 eyes of 36 dogs selected for the study
were randomly divided into 6 treatment groups as EC and
ET (early KCS), LC and LT (late KCS), and RC and RT
(reflex KCS). The groups EC, LC, and RC were subjected to
treatment with tacrolimus 0.1% ointment (Talimus, Ajanta
Pharma Limited, Mumbai, India), applied once a day for
2 months, and groups ET, LT, and RT were subjected to
treatment with CsA 0.05% eye drops (Cyclomune, Sun
Pharmaceutical Industries Ltd., Halol, Gujarat, India)
instilled five times a day for 60 days (Table 1). In addition
to medical management, tarsorrhaphy was performed in
the RC and RT groups. Alpha-tocopherol capsules (Evion,
Merck Limited, Mumbai, India) and omega-3 essential
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Table 1. Grouping of patients and protocols used for the treatment of KCS.
Groups
Group E
Group L
Group R

Treatment groups

Medical/surgical management

Treatment protocol

Number of eyes

EC

Medical

Cyclosporine (0.05%)

10

ET

Medical

Tacrolimus (0.1%)

11

LC

Medical

Cyclosporine (0.05%)

11

LT

Medical

Tacrolimus (0.1%)

10

RC

Medical

Cyclosporine (0.05%)

10

RT

Medical

Tacrolimus (0.1%)

6

fatty acid syrup (FILO-VET, VC Pharmaceuticals,
Ernakulam, Kerala, India) were also supplemented along
with treatment in all the groups.
2.2. Posttreatment evaluation
The effect of treatment was assessed by analysis of digital
photographs taken on the 0th (day of presentation), 15th,
30th, and 60th posttreatment days and by scoring various
parameters (20) as mentioned hereafter. Conjunctival
hyperemia was scored from 0 to 2 as 0: no conjunctival
hyperemia, 1: mild hyperemia, and 2: moderate hyperemia.
Ocular discharge was scored from 0 to 2 as 0: no ocular
discharge, 1: slight ocular discharge at the medial canthus,
and 2: discharge across the cornea or on eyelid margins.
The area of corneal pigmentation was demarcated as
within the area of a clock by dividing the cornea into 3
circular parts and was scored from 0 to 4 as 0: no corneal
pigmentation, 1: pigment over less than 25% of the cornea,
2: pigment over 25%–50% of the cornea, 3: pigment over
50%–75% of the cornea, and 4: pigment over >75% of the
cornea. The corneal pigment density was scored from 0
to 3 as 0: no pigment, 1: iris easily visualized through the
pigment, 2: iris partially visualized through the pigment,
and 3: iris not visible through the pigment. The corneal
vessel length was scored from 0 to 3 as 0: no corneal vessels,
1: limbal corneal vessels, 2: vessels halfway towards the
corneal axis, and 3: vessels extending to the axial cornea.
The corneal vessel density was scored from 0 to 4 as 0: no
vessels, 1: vessels extending to the cornea from <25% of
the circumference of the limbus, 2: vessels extending to the
cornea from 25%–50% of the circumference of the limbus,
3: vessels extending to the cornea from 50%–75% of the
circumference of the limbus, and 4: vessels extending to
the cornea from >75% of the circumference of the limbus.
The clarity of the cornea was assessed based on visual
examination and was scored from 1 to 4 as 1: clear, 2: hazy,
3: moderate opacity, and 4: complete opacity; the depth of
corneal ulceration was scored from 0 to 3 as 0: no ulcer,
1: shallow ulcer, 2: moderate ulcer, and 3: deep ulcer (21).
2.3. Statistical analysis
Data were analyzed statistically using SPSS 22.0 (IBM
Corp., Armonk, NY, USA). Summary statistics (mean

± SE and median ± SE) were calculated for all variables.
Single measurements of continuous variables between
groups E, L, and R were compared using one-way analysis
of variance (ANOVA). Continuous data of the parametric
variable (STT) within and between groups EC, ET, LC,
LT, RC, and RT at different time intervals were analyzed
using repeated-measures ANOVA. For both one-way
ANOVA and repeated-measures ANOVA, the post hoc
Tukey’s HSD test was employed. An independent samples
t-test was used to compare the parametric data at different
time intervals between EC and ET, LC and LT, and RC
and RT. Nonnormally distributed data or nonparametric
variables (scores) on different days were compared using
the Kruskal–Wallis test. Dunn’s test was used for analyzing
pairwise differences in groups if there was a tied rank for
the Kruskal–Wallis test (22). The Wilcoxon signed rank
test was used to evaluate nonparametric data at different
time intervals within a group. The level of significance was
set to P < 0.05.
3. Results
The average age of dogs with KCS in the study was 3 years
and most of the animals were in the age group of 1 to 5
years. Nearly 61% of the affected animals were female.
Breeds like Chinese pugs, Indian Spitz, German shepherd,
and Mastiff were found to be commonly affected. The mean
± SE values of physiological, hematological, and serum
biochemical parameters did not show any significant
variation (P > 0.05) between groups E, L, and R except for
eosinophil count (Table 2) and the mean values of each
parameter remained within normal limits. Eosinophil
values were significantly higher (P < 0.05) in group E
compared to group L.
On the day of presentation, the menace reflex was
significantly higher (P < 0.05) in group E compared to
groups L and R, whereas the amount of ocular discharge was
significantly higher (P < 0.05) in groups L and R compared
to group E before the initiation of either of the treatments
(Table 3). Corneal clarity was significantly higher (P <
0.05) in group R (opaque), followed by groups L and E,
respectively (Table 3). The score for corneal ulceration was
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Table 2. Mean ± SE values of physiological, hematological, and biochemical parameters of dogs in groups E, L, and R on day 0.
Parameters

Group E (n = 16)

Group L (n = 12)

Group R (n = 8)

RT (°C)

39.42 ± 0.07

39.32 ± 0.10

39.3 ± 0.06

RR (breaths/min)

33.76 ± 1.12

34.00 ± 1.11

36.31 ± 0.67

HR (beats/min)

112.5 ± 1.64

105.4 ± 2.71

109.1 ± 2.55

Hb (g/dL)

12.58 ± 0.31

12.07 ± 0.39

12.81± 0.30

PCV (%)

38.24 ± 0.82

37.48 ± 1.39

39.0 ± 1.10

RBC (×10 /µL)

4.579 ± 0.08

4.420 ± 0.10

4.69 ± 0.12

WBC (×10 /L)

16746 ± 792.7

20169 ± 1395

19344 ± 856.7

Glucose (mg/dL)

93.5 ± 1.62

99.43 ± 2.47

96.69 ± 2.19

Neutrophils (%)

73.86 ± 1.38

75.52 ± 1.56

74.19 ± 1.65

Lymphocytes (%)

13.90 ± 1.22

13.00 ± 0.98

11.69 ± 0.77

Monocytes (%)

2.905 ± 0.33

3.524 ± 0.35

3.50 ± 0.38

Eosinophils (%)

1.333 ± 0.28

0.571 ± 0.14

0.93 ± 0.23ab

Basophils (%)

0.00 ± 0.00

0.00 ± 0.00

0.06 ± 0.06

TSH (µg/L)

0.29 ± 0.01

0.31 ± 0.01

0.31 ± 0.03

T4 (nmol/mL)

4.12 ± 1.06

2.74 ± 0.49

6.39 ± 2.31

T3 (nmol/mL)

0.40 ± 0.09

0.35 ± 0.05

0.60 ± 0.11

Cortisol (nmol/L)

28.08 ± 1.57

31.46 ± 0.98

28.95 ± 1.72

6

9

a,b

a

b

Differ significantly (P < 0.05) between groups.

Table 3. Mean ± SE and median ± SE values of scores of ophthalmic parametric and nonparametric variables of dogs in groups E, L,
and R on day 0.
Parameter

E (n = 16)

L (n = 12)

R (n = 8)

Menace reflex

1.81 ± 0.09a

0.71 ± 0.20b

0.13 ± 0.09b

Palpebral reflex

1.91 ± 0.07

1.67 ± 0.11

1.88 ± 0.09

Conjunctival hyperemia

0.81 ± 0.19

1.05 ± 0.16

Ocular discharge

1.14 ± 0.10

Corneal clarity

1.06 ± 0.11
b

1.71 ± 0.10

1.63 ± 0.13b

1.61 ± 0.18a

2.66 ± 0.27b

3.62 ± 0.17c

Corneal ulceration

0.14 ± 0.08a

0.57 ± 0.16a

2.56 ± 0.16b

Corneal vessel length

0.14 ± 0.1a

0.38 ± 0.16ab

0.94 ± 0.23b

Corneal vessel density

0.14 ± 0.1a

0.38 ± 0.15a

1.31 ± 0.27b

Corneal pigmentation area

1.14 ± 0.24

2.33 ± 0.38

1.25 ± 0.27

Corneal pigmentation density

1.33 ± 0.25

1.81 ± 0.27

1.81 ± 0.28

STT (mm/min)

11 ± 0.58a

4.19 ± 0.23b

18.5 ± 1.35c

FDT

0.14 ± 0.14a

1.29

RBD test

3.14 ± 0.31a

4.48 ± 0.21b

a,b,c

Differ significantly (P < 0.05) between groups.
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significantly higher (P < 0.05) in group R compared to
the other two groups. The degree of corneal vessel length
and degree of corneal vessel density were also significantly
higher (P < 0.05) in group R compared to group E (Table
3). Fluorescein dye retention was significantly higher (P <
0.05) in group R, whereas the RBD test showed significantly
higher (P < 0.05) retention in groups L and R compared to
group E. Since the dogs in the study were grouped on the
basis of STT values, significantly higher (P < 0.05) mean ±
SE values of the STT were recorded in group R, followed
by groups E and L, respectively (Table 3).
The post treatment mean ± SE STT scores showed
significant improvement (P < 0.05) in tear production from
day 15 in groups E and L following treatment with either
0.1% tacrolimus or 0.05% CsA (Figure 1). Group R also
showed marked improvement in tear production. There
was no significant difference (P < 0.05) in the efficacy of
CsA 0.05% eye drops and tacrolimus 0.1% ointment as
lacrimostimulants when applied 5 times daily and as a
single application daily, respectively. In group R with KCSassociated corneal ulceration, pretreatment STT scores
showed near normal tear production. Although topical
application of either of the lacrimostimulants enhanced
tear production in this group, the rise in tear production
was statistically insignificant.
The basic ocular reflexes associated with vision
like menace reflex and pupillary light reflex improved
significantly (P < 0.05) with treatment in all the groups.
Conjunctival hyperemia also improved significantly (P <
0.05) in all groups with either of the treatments (Figure 2).
There was no significant difference between two treatments
in any of the treatment groups. In groups E and L, significant
improvement (P < 0.05) was evident from day 30 onwards,
whereas in group R, significant improvement (P < 0.05)
was observed by day 15. Scores for ocular discharge also
showed significant improvement (P < 0.05) from day 30 in

all groups irrespective of treatments (Figure 3). In group L,
treatment with 0.1% tacrolimus significantly reduced (P <
0.05) mucoid ocular discharge from day 15 (Figure 3). The
corneal clarity significantly increased (P < 0.05) in group
R from day 15 onwards with 0.1% tacrolimus treatment
(Figure 4). Integrity of corneal epithelium was found to
increase significantly (P < 0.05) in group R compared to
the other two groups from day 15. The healing of corneal
ulcers did not differ significantly (P < 0.05) with either of
the treatment protocols in groups E and R, but the loss
in corneal epithelium was significantly less (P < 0.05) in
group LT compared to group LC on day 15. Posttreatment
parameters like corneal vessel length, corneal vessel density,
and corneal pigmentation area did not show a significant
variation (P > 0.05) from pretreatment values at any interval
of time between any groups, except in group R. Group RC
showed a significant increase (P < 0.05) in corneal vessel
length on day 15. There was a significant decrease (P < 0.05)
in corneal vessel density in groups RC and RT by day 60.
In groups LC and LT, vascularity was less visible because
of corneal pigmentation. The corneal pigmentation density
significantly increased (P < 0.05) in groups EC and RC from
day 30 and day 15, respectively (Figure 5). No significant
increase (P < 0.05) in corneal pigmentation density was
observed between any other treatment groups. It was
observed that the progression of pigmentation was less
among 0.1% tacrolimus groups compared to 0.05% CsA
groups. Fluorescence dye retention was significantly less (P
< 0.05) in groups RC and RT from day 30 onwards. There
was significant reduction (P < 0.05) in RBD uptake in all
the treatment groups from day 15 and a significant decrease
(P < 0.05) in RBD retention in group ET compared to
group EC at day 30 (Figure 6). Photographs of eyes of KCSaffected dogs representing each treatment group at different
intervals of time were also recorded to depict the effect of
treatment (Figure 7).
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Figure 6. Mean ± SE values of the score for retention in RBD test;
: differ significantly (P < 0.05) compared to day 0.

4. Discussion
The results of this study support the use of both CsA
0.05% eye drops, instilled five times daily, and tacrolimus
0.1% ointment, applied once daily, for improving tear
production in dogs affected with KCS and to reduce the
deteriorating clinical signs associated with KCS. There was
a marked increase in tear production in all dogs treated
with either of the two drugs within 2 weeks. For arresting
the progression of corneal pigmentation associated with
KCS, tacrolimus 0.1% ointment was more effective than
CsA 0.05% eye drops. Tacrolimus 0.1% ointment showed
better response in stimulating the tear production and
arresting the progression of corneal pigmentation even
in dogs with low STT values. Although the concentration
of tacrolimus used in our study differs from earlier
investigations, the results corroborated the findings of a
previous study (9).
The efficacy of both the drugs was evaluated in dogs
that had not received any previous treatment for KCS.
The half-life of CsA, when administered topically, is

not available in the literature, but it is believed to reach
therapeutic concentrations in corneal tissue quickly
(23). Investigations have shown a significant degree of
penetration of CsA into inflamed tissue (24). Previous
studies have shown CsA at 0.1% to be effective in the
treatment of KCS in canines (25). On the other hand,
tacrolimus is 10 to 100 times more potent than CsA in
vitro (26) and hence a single application was advised.
Today 0.1% and 0.03% tacrolimus preparations are widely
used in veterinary ophthalmic therapy (9,20,27). Studies
in experimental animal models have already demonstrated
extremely low blood concentrations of tacrolimus after
topical administration (15) and hence systemic adverse
effects are seldom anticipated, providing short-term safety
in clinical use. Topical broad-spectrum antibiotics are
often used for the management of KCS since secondary
bacterial infection is considered as a major sequel of KCS
(28). Despite the use of topical antibiotics, both 0.1%
tacrolimus and 0.05% CsA effectively reduced the mucoid
discharge that developed with defective tearing.
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Figure 7. Follow-up photographs of dogs representing each group (EC, ET, LC, LT, RC, and RT) on days 0, 15, 30, and 60.
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The STT is the commonly employed diagnostic test to
detect KCS. The mean normal value of the STT is 20 mm/
min in dogs and 17 mm/min in cats (16). The normal range
of STT readings is 15–25 mm/min. Values of 0–9 mm/min
were considered to demonstrate KCS while values of 10–
14 mm/min were considered as borderline tear deficiency
(29). For a comprehensive investigation of the effects of the
drugs used in our study, we classified KCS into different
stages based on STT readings as recorded on the first
day of presentation. Mild to moderately low STT values
between 6 mm/min and 14 mm/min were considered as
early KCS and a severely low STT value of lower than 5
mm/min was considered as late KCS. Such a classification
was not identified in literature. Posttreatment STT scores at
different intervals improved with both CsA and tacrolimus
at their respective concentrations. A quantitative difference
in tear production was not observed between 2% CsA
and 0.03% tacrolimus up to 12 weeks in a previous study
(20). Interestingly, the concentration of the drugs used for
evaluation in the above study was proportionately similar
to that used in our study.
The response to menace reflex improved with increase
in corneal clarity and decrease in inflammation. An
improperly moistened cornea loses its shine and becomes
opaque in KCS (27). The rise in tear production once the
treatment was initiated might have contributed to the
corneal lubrication and thereby restoration of corneal
integrity. Corneal clarity increased consistently in dogs
presented with corneal ulceration-induced reflex tearing
also. Although a significant relationship was not observed
in corneal healing time, the dogs that developed corneal
ulceration due to KCS with reflex tearing under 0.05% CsA
therapy showed faster healing compared to dogs under 0.1%
tacrolimus treatment, possibly due to the low degree of
corneal ulceration in the former group compared to that in
the latter. Clinical improvement in pupillary light reflex was
also observed during the healing phase of the corneal ulcer.
The drastic reduction in mucoid discharge in parallel to
the rise in tear production was evident in all the dogs with
either of the drugs during the course of treatment. Both
CsA and tacrolimus also have antibacterial activity (30).
In a previous study, dogs treated with 0.2% CsA ointment
two times a day showed a reduction in lacrimal gland
inflammation and regeneration of lacrimal acinar lobules
(12). In our study, we used a lower concentration of CsA
(0.05%) instilled regularly in a much shorter interval of
time. CsA as 0.2% ointment or 1% to 2% drops is inherently
capable of reducing the infiltration of T lymphocytes into
the lacrimal gland acini and their proliferation, and it
promotes apoptosis, thereby decreasing inflammation
(9,31). Since tacrolimus is more potent than CsA, a single
application could stimulate sufficient tear production and
suppress infection and inflammation associated with KCS.
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The CsA and tacrolimus at their respective concentrations
and time intervals of application in our study could
appreciably improve the conjunctival clarity and mucoid
discharge in KCS-affected eyes. In a previous clinical
study that compared 2% CsA with 0.03% tacrolimus in
KCS-affected dogs, no significant difference was found in
combined clinical scores for conjunctival hyperemia and
ocular discharge (20). Interestingly, an early reduction
in mucoid discharge was observed with 0.1% tacrolimus
compared to 0.05% CsA in our study.
The corneal neovascularization remained dormant once
treatment using either of the drugs was initiated. Although
topical CsA and tacrolimus effectively inhibit T-lymphocyte
proliferation and inflammatory prostaglandins responsible
for the corneal neovascularization (30), it may take a
longer time for a significant decrease in vascularity to be
achieved in addition to the lower concentration of both the
drugs used in our study. Corneal vascularization resolved
when topical CsA ointment was used at 0.2% twice a day
for chronic keratitis in a previous study (24). The initial
increase in corneal vessel length in the reflex tear group
with corneal ulceration could be attributed to healing in the
corneal epithelium, which demands neovascularization.
Confining and reducing corneal pigmentation is the
most challenging aspect while treating KCS. Corneal
pigmentation progresses with the in-growth of pigmented
conjunctival epithelial cells following persistent corneal
epithelial injury and when the depth of injury exceeds the
regenerative capabilities of the resident corneal epithelial
cells (32). This is because the melanocytes at the limbus,
which act as a final line of defense against oxidative damage
in the cornea, initiate to play their role as scavengers of
free radicals (33). The 0.05% CsA could not arrest the
progression of corneal pigmentation in dogs with KCS
and led to a slower progression of pigmentation over time,
but the spread of corneal pigmentation was less in dogs
treated with 0.1% tacrolimus. Rather, the concentration
of CsA may not have been enough to contend with
the reactive oxygen species to arrest the spread of
pigmentation. Contradictory reports exist regarding the
efficacy of 1% and 2% CsA in inhibiting the progression
of pigmentation and resolving pigmentation completely
(25,27,34). Unfortunately, in dogs with ulcerative keratitis
and reflex tearing, there was an initial increase in the
pigment deposition. The topical 0.1% tacrolimus more
effectively controlled the progression of pigmentation in
these dogs as compared to 0.05% CsA by day 60. However,
both 0.05% CsA and 0.1% tacrolimus could not reduce
or completely resolve the pigmentation that was already
established on the cornea. Previous studies with 2% CsA
and 0.03% tacrolimus also showed similar results (20).
Tacrolimus has been found to be effective in dogs
unresponsive to cyclosporine therapy for stimulating
tear production (20,23) and for arresting the progression
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of corneal pigmentation (9). Although tear production
improved with both 0.05% CsA and 0.1% tacrolimus, an
evaluation of the effect of 0.1% tacrolimus, particularly in
dogs, where the progression of pigmentation could not be
arrested amply by 0.05% CsA, is lacking in our study.
In conclusion, both tacrolimus 0.1% ointment and CsA
0.05% eye drops improve tear production in KCS-affected
dogs. Topical tacrolimus 0.1% ointment effectively arrests
the progression of pigment epithelium compared to CsA
0.05% eye drops in KCS-affected dogs.
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